Skip to content

A randomised, controlled, evaluator-blinded clinical trial of the clinical efficacy and safety of nutritional supplements for the treatment of mild to moderate rosacea

A randomised, controlled, evaluator-blinded clinical trial of the clinical efficacy and safety of nutritional supplements for the treatment of mild to moderate rosacea

Status
Recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400085311
Enrollment
Unknown
Registered
2024-06-05
Start date
2024-07-01
Completion date
Unknown
Last updated
2024-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rosacea

Interventions

Test group:AKG Nutritional Supplements
Control group:AKG Blank Capsules

Sponsors

Xiangya Hospital of Central South University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 30 Years

Inclusion criteria

Inclusion criteria: (1) Age: 18-30 years old; (2) Patients with mild rosacea (phenotype of persistent erythema or papular pustules, CEA score =2, IGA score =2);(3) Moderate rosacea patients (phenotype of persistent erythema or papular pustules, CEA score = 3, IGA score = 3) who refused conventional drug treatment; (4) Voluntary signed informed consent.

Exclusion criteria

Exclusion criteria: (1) Patients with gastric diseases such as dyspepsia, gastric acid deficiency, gastric ulcers, etc;(2) Patients with systemic diseases such as moderate to severe liver, kidney, lung or blood diseases; (3) Patients with depression or mental disorders;(4) Patients with rosacea with hyperplasia as the main clinical manifestation, or with the facial manifestation of other facial dermatological disorders (e.g., seborrheic dermatitis, eczema, etc.) or other systemic diseases (e.g., dermatomyositis, systemic lupus erythematosus) ;(5) Participation in any clinical trial within one month;(6) Use of other dietary supplements or nutrients within one month prior to the start of the study; (7) Receipt of any other form of treatment for rosacea within one month prior to the start of the study; (8) Allergy to the ingredients of AKG; (9) Females in the preparatory period, during pregnancy, and during breastfeeding;(10) Any other conditions that, in the opinion of the investigator, do not allow for enrollment in the study. Translated with www.DeepL.com/Translator (free version)

Design outcomes

Primary

MeasureTime frame
Rosacea Clinical Symptom Severity Assessment (Physician Assessment);Rosacea Clinical Symptom Severity Assessment (Patient Assessment);

Secondary

MeasureTime frame
Rating of existing skin lesions (physician evaluation);Paroxysmal flushing (patient evaluation);Skin Life Quality Index (DLQI) Questionnaire;

Countries

China

Contacts

Public ContactBen Wang

Xiangya Hospital Central South University

wangben0804@163.com+86 138 7588 5737

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026